Dr. Marshall on Next Steps Following Y-90 in Liver-Metastatic CRC
In Partnership With:
John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).
John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).
If a a survival advantage is observed in these patients, Marshall believes that this will lead to a fairly significant shift in practice for this patient population. This is especially in part to the increasing partnership reliance on interventional radiology in multidisciplinary care for CRC that is also extending out to other cancers. This is also being explored in pancreatic cancer, gastric cancer, and other tumors where liver-dominant metastases are an issue.
Regarding Y-90, Marshall says there is likely to be next-generation or other techniques that will work to improve liver-metastatic disease.
